Can a CVP set restore amniotic fluid and improve newborn health?

NCT ID NCT07774832

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial compares two methods of amnioinfusion—adding fluid to the womb—in pregnant women with preterm premature rupture of membranes (PPROM) and very low amniotic fluid. One method uses a central venous pressure (CVP) set for controlled fluid delivery, while the other uses the standard transabdominal approach. The study aims to see if the CVP-set method better restores amniotic fluid levels and improves outcomes like birth weight and Apgar scores. Forty women with PPROM at 24-26 weeks of pregnancy will be enrolled and followed through delivery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CVP-set amnioinfusion with McDonald cerclage
What this could lead to
If effective, this technique could offer a safer, more controlled way to restore amniotic fluid in PPROM, potentially improving pregnancy and newborn outcomes.
What could go wrong
This is a small, non-randomized study, so results may not be conclusive. The procedure carries risks of infection or complications, and benefits over conventional amnioinfusion are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jan 2021

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Singleton pregnancy. * Preterm premature rupture of membranes (PPROM) at 24-26 weeks of gestation. * Oligohydramnios with an amniotic fluid index (AFI) \<2 cm. * Provided informed consent to participate in the study. Exclusion Criteria: * Presence of uterine contractions. * Clinical or laboratory signs of intrauterine infection. * Pregnancy complications requiring immediate termination of pregnancy, including hypertension, preeclampsia, HELLP syndrome, or other significant maternal conditions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Oligohydramnios are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fkik Unja Rsud Mattaher Jambi

    Jambi City, Jambi, 36361, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.